Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California
- PMID: 29451695
- PMCID: PMC6911353
- DOI: 10.1002/cncr.31296
Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California
Abstract
Background: To the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML).
Methods: Using linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged ≥18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death ≤60 days from diagnosis).
Results: Of the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCI-CCs were more likely to be aged ≤65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P = .010) and lower rates of respiratory failure (11% vs 14%; P = .003) and cardiac arrest (1% vs 2%; P = .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs.
Conclusions: The initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45. © 2018 American Cancer Society.
Keywords: acute myeloid leukemia (AML); complications; early mortality; epidemiology; health services; location of care.
© 2018 American Cancer Society.
Conflict of interest statement
The authors have no relevant conflicts of interest to disclose.
Figures
Similar articles
-
Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.Br J Haematol. 2017 Jun;177(5):791-799. doi: 10.1111/bjh.14631. Epub 2017 Apr 17. Br J Haematol. 2017. PMID: 28419422 Free PMC article.
-
Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina.Cancer. 2016 Oct;122(19):3041-50. doi: 10.1002/cncr.30139. Epub 2016 Jun 28. Cancer. 2016. PMID: 27351768
-
Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.Cancer. 2022 Jan 1;128(1):139-149. doi: 10.1002/cncr.33873. Epub 2021 Aug 26. Cancer. 2022. PMID: 34436782
-
Tobacco Treatment Programs at National Cancer Institute-designated Cancer Centers: A Systematic Review and Online Audit.Am J Clin Oncol. 2019 Apr;42(4):407-410. doi: 10.1097/COC.0000000000000522. Am J Clin Oncol. 2019. PMID: 30724778 Free PMC article.
-
Geospatial approaches to cancer control and population sciences at the United States cancer centers.Cancer Causes Control. 2018 Mar;29(3):371-377. doi: 10.1007/s10552-018-1009-0. Epub 2018 Feb 8. Cancer Causes Control. 2018. PMID: 29423759 Free PMC article. Review.
Cited by
-
Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study.BMC Cancer. 2022 Nov 3;22(1):1127. doi: 10.1186/s12885-022-10231-0. BMC Cancer. 2022. PMID: 36324111 Free PMC article.
-
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.J Clin Oncol. 2022 Nov 10;40(32):3709-3718. doi: 10.1200/JCO.22.00307. Epub 2022 Jun 13. J Clin Oncol. 2022. PMID: 35696629 Free PMC article.
-
Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment.Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020009. doi: 10.4084/MJHID.2020.009. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 31934319 Free PMC article. Review.
-
Disparities in treatment and survival in early-stage hepatocellular carcinoma in California.J Surg Oncol. 2023 Dec;128(8):1302-1311. doi: 10.1002/jso.27423. Epub 2023 Aug 23. J Surg Oncol. 2023. PMID: 37610042 Free PMC article.
-
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Cancer. 2023 Apr 1;129(7):1017-1029. doi: 10.1002/cncr.34609. Epub 2023 Jan 30. Cancer. 2023. PMID: 36715486 Free PMC article.
References
-
- Deschler B, Lubbert M: Acute myeloid leukemia: epidemiology and etiology. Cancer 107:2099–107, 2006 - PubMed
-
- Ferrara F, Schiffer CA: Acute myeloid leukaemia in adults. Lancet 381:484–95, 2013 - PubMed
-
- Hahn A, Giri S, Yaghmour G, et al.: Early mortality in acute myeloid leukemia. Leuk Res 39:505–9, 2015 - PubMed
-
- Higby DJ, Cohen E, Holland JF, et al.: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 14:440–6, 1974 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical